Drugs / Peginterferon alpha-2b
Peginterferon alpha-2b
also known as
Peg-Intron · Peg-IFN-α2b · PegIFNa2b · PegIFNα-2b (PegIntron) · Peginterferon α-2b (PEG) · SCH54031
Trials 9
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00303290 | Jan 2000 → Nov 2014 | chronic myeloid leukemia | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05203055 | Dec 2021 → Dec 2022 | chronic hepatitis B virus infection | Fuzhou General Hospital | Unknown | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT01872442 | Oct 2013 → Oct 2018 | chronic myeloid leukemia | Poitiers University Hospital | Completed | No outcome recorded |
| Phase 2 | NCT00846430 | Oct 2008 → Apr 2017 | neurofibromatosis type 1 | Corewell Health West | Completed | No outcome recorded |
| Phase 2 | NCT00585221 | Jul 2007 → Jul 2009 | brain cancer, gastrointestinal stromal tumor | University of Utah | Terminated | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT01590225 | Jan 2013 → Aug 2021 | chronic hepatitis C virus infection | Merck Sharp & Dohme LLC | Withdrawn | No outcome recorded |
| Phase 3 | NCT00381017 | Sep 2006 → ? | HIV infectious disease, cirrhosis of liver, hepatitis C virus infection | Merck Sharp & Dohme LLC | Withdrawn | No outcome recorded |
| Phase 42 trials · 1 met primary | ||||||
| Phase 4 | NCT02247440 | Aug 2014 → May 2017 | HIV infectious disease, chronic hepatitis C virus infection | Research Institute for Development | Completed | No outcome recorded |
| Phase 4 | NCT01928511 | Jan 2014 → Dec 2018 | chronic hepatitis B virus infection | Seng Gee Lim | Completed | Met primary |
| Comparator or background therapy3 trials | ||||||
| Phase 2 | NCT00148837 Background | Sep 2004 → Dec 2008 | chronic hepatitis C virus infection | French National Agency for Research on AIDS and Viral Hepatitis | Completed | No outcome recorded |
| Phase 3 | NCT01290679 Background | Mar 2011 → Feb 2013 | hepatitis C virus infection | Janssen R&D Ireland | Completed | Met primary |
| Phase 3 | NCT00248339 Comparator | May 2002 → Jul 2005 | hepatitis C virus infection | Virginia Commonwealth University | Completed | No outcome recorded |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 14 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | peginterferon-alpha2b | “We conducted a randomized controlled trial of CHB patients on NA >12 months with HBV DNA(-) randomized to switch or add-on peginterferon-alpha2b (1.5 μg/kg/weekly) for 48 weeks...” PMID 33895361 ↗ Apr 202113“Peg-interferon alpha 2-b (a subcutaneous injection of 1.5 micrograms/kg once a week)” NCT02247440 ↗ “Peg Interferon Alpha 2b (Peg Intron)” NCT00303290 ↗ |
| Known as | Peg-IFN-α2b | “dasatinib combined to Peg-IFN-α2b (Dasa-PegIFN, NCT01872442)” PMID 36214090 ↗ Oct 2022 |
| Known as | Peg-Intron | “This is a Phase 3b, randomized, open-label, parallel-group, multi-center, multi-national study of low-dose maintenance Peg interferon alpha-2b (Peg-Intron®) in subjects with...” NCT00381017 ↗3“Peginterferon α-2b (PEG), 1.5 μg/kg, will be administered weekly by subcutaneous injection for the specified period of time (see Study Design, Arms A and B). Pegintron® (MSD...” NCT01928511 ↗ “Peg Interferon Alpha 2b (Peg Intron)” NCT00303290 ↗ “Peginterferon-alpha-2b (PEG-Intron)” NCT00248339 ↗ |
| Known as | PegIFNa2b | “Peginterferon-alpha 2b (PegIFNa2b);” NCT00585221 ↗ |
| Known as | PegIFNα-2b (PegIntron) | “PegIFNα-2b (PegIntron)” NCT01290679 ↗ |
| Known as | Peginterferon α-2b (PEG) | “Peginterferon α-2b (PEG), 1.5 μg/kg, will be administered weekly by subcutaneous injection for the specified period of time (see Study Design, Arms A and B). Pegintron® (MSD...” NCT01928511 ↗ |
| Known as | SCH54031 | “Therapy of Early Chronic Phase Chronic Myelogenous Leukemia (CML) With SCH54031 (PEG Interferon Alpha 2B/PEG Intron) and Low-Dose Cytosine Arabinoside (Ara-C)” NCT00303290 ↗ |
| Modality | Protein / enzyme biologic | “a new interferon” NCT00303290 ↗ |
| Route | Subcutaneous | “0.5 µg/kg subcutaneously once weekly for 24-36 months” NCT00381017 ↗ |